Bruker has announced a significant investment in Germany-based company RECIPE Chemicals + Instruments, which provides mass spectrometry-based diagnostic assay kits.
The transaction’s financial aspects remain undisclosed.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The German company offers vendor-agnostic therapeutic drug monitoring (TDM) and in vitro diagnostic kits that are compatible with liquid chromatography-mass spectrometry (LC–MS)/MS, high-performance liquid chromatography (HPLC), and inductively coupled plasma mass spectrometry (ICP-MS) assays.
RECIPE’s managing director Dr Gernot Wolfram spearheads the company’s operations.
Bruker noted that the investment and partnership bolster its offerings in small-molecule clinical diagnostic assays through the integration of ClinMASS kits of RECIPE with Bruker’s EVOQ liquid chromatography triple-quadrupole mass spectrometers and with LC-TQ-MS systems from other manufacturers.
Furthermore, both entities are working to launch chromatography-free (chrom-free) RECIPE ClinDART kits that will operate on the EVOQ-DART TQ systems, allowing transitions between traditional LC-TQ-MS techniques and the high-throughput ClinDART processes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe EVOQ-DART TQ system, in its chrom-free mode, provides throughput for multiplex assays without the need for chromatography while ensuring sensitivity and quantitation through triple-quad mass spectrometry selectivity and multiple-reaction monitoring (MRM) features.
The ClinDART platform enhances sustainability by decreasing solvent consumption by 95%, reducing expenses, and boosting productivity of labs.
It complements RECIPE’s ClinMASS LC-TQ assay offerings and aims to establish new benchmarks for high-throughput TDM, drug screening for abuse, and various other applications.
Bruker Applied Mass Spectrometry senior vice-president Jeffrey Zonderman said: “This majority investment aligns with our strategic vision for LC-TQ-MS assays, enhanced with novel chrom-free assays based on our proprietary DART technology to lead in clinical research and regulated TDM markets.
“The RECIPE ClinMASS and novel ClinDART assays, combined with LC or chrom-free EVOQ DART-TQ methods, are expected to offer unparalleled flexibility, throughput, and cost-effectiveness.”
In June 2024, Bruker launched the neofleX Imaging Profiler MALDI-TOF/TOF for mass spectrometry imaging applications.
